// App-Quantinova.ai

AB0289 : EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK

Researchers

Presenter

  • R. Fleischmann

Principal Investigators

  • D. Alvarez

  • A. Bock

  • C. Cronenberger

  • I. Vranic

  • W. Zhang

  • R. Alten

Medical Centers

  • Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, United States

  • Pfizer Inc., Collegeville, United States

  • Cardiio Inc., Cambridge, United States of America

  • Pfizer Inc., Tadworth, United Kingdom

  • Pfizer Inc, Lake Forest, United States of America

  • Schlosspark-Klinik University Medicine, Berlin, Germany

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Telomerase reverse transcriptase

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multinational

  • Parallel Group

Phase

  • III

Study Id's

  • NCT02480153

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved